Home›Stock Screener›Windlas Biotech

Windlas Biotech Share Price Today | Stock Price & Windlas Biotech Share Screener

WINDLAS Pharmaceuticals
Live Share Price NSE
₹1017.90
▼ -64.50 (-5.96%)
2026-10-05 00:00:00
Live Share Price BSE
₹1018.00
▼ -65.20 (-6.02%)
2026-10-05 00:00:00

As of October 5, 2026, the live Windlas Biotech share price (NSE: WINDLAS) is ₹1,017.90 on NSE and ₹1,018.00 on BSE, down 5.96% from the previous close, with shares trading between ₹1,009.00 and ₹1,094.10 in today's trading session, and a 52-week range of ₹705.75–₹1,154.75. Check WINDLAS annual price range for the annual price range and momentum. Use the Windlas Biotech stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Windlas Biotech opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹208 and net income of ₹16, with EBITDA of ₹31, an operating margin of 13.0% and a profit margin of 7.7%.

Windlas Biotech Market Cap ₹1,532.95 Cr.
WINDLAS P/E Ratio (TTM) 22.70
Windlas Biotech P/B Ratio 2.84
EPS (TTM) ₹29.19
Dividend Yield 0.80%
Debt to Equity 0.04
WINDLAS 52 Week High ₹1154.75
Windlas Biotech 52 Week Low ₹705.75
Operating Margin 13.00%
Profit Margin 7.69%
WINDLAS Revenue (TTM) ₹208.00
EBITDA ₹31.00
Net Income ₹16.00
Total Assets ₹761.00
Total Equity ₹506.00

Windlas Biotech Share Price Chart

Track the current stock price of Windlas Biotech with an interactive chart. Analyse WINDLAS share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Windlas Biotech stock quote in one place.

The quote of ₹1,017.90 sits between the 52-week low of ₹705.75 and the 52-week high of ₹1,154.75, and the latest session moved -5.96% from the previous close.

Windlas Biotech Company Profile - Fundamental Screener

Screen Windlas Biotech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for WINDLAS shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE0H5O01029.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE0H5O01029

Windlas Biotech Balance Sheet Screener

Screen WINDLAS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2025, total assets were ₹761, up from ₹626 in 2024.

Latest statistics put total assets at ₹761 and shareholder funds at ₹506, with a leverage ratio of 0.04.

Item 2025 2024 2023 2022 2021 2020 2019 2018

Assets

Total Assets 761 626 529 491 296 339 298 290
Current Assets 525 431 354 382 194 168 121 144
Fixed Assets 223 179 109 91 96 70 64 87

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0
Current Liabilities 5 5 6 2 4 4 8 22
Non-Current Liabilities 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 506 450 402 395 199 210 194 125
Share Capital 11 10 11 11 6 6 6 6
Reserves & Surplus 495 440 392 384 193 203 187 117

Windlas Biotech Income Statement Screener - Profit & Revenue Analysis

Screen Windlas Biotech income statement and profit fundamentals. Analyze WINDLAS quarterly results. Windlas Biotech reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2025-Mar, revenue was ₹208 and net profit was ₹16, equal to earnings per unit of ₹7.77, at an operating margin of 13%.

In that period expenses were ₹177, interest cost ₹1 and tax ₹5. The next period listed, 2025-Jun, shows revenue of ₹215 and net profit of ₹18.

Item 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun 2022-Sept

Revenue and Expenses

Revenue 208 215 226 238 176 179 192 199 143 147 156 165 125 123 135
Expenses 177 184 194 209 149 154 164 170 124 128 134 142 108 106 117

Operating Costs and Margins

EBITDA 31 32 32 29 26 25 28 29 19 20 22 24 17 17 19
Operating Profit % 13.00% 13.00% 13.00% 10.00% 13.00% 12.00% 12.00% 13.00% 12.00% 12.00% 12.00% 13.00% 11.00% 12.00% 12.00%
Depreciation 8 7 8 8 4 6 7 7 4 3 3 3 3 3 3
Interest 1 1 1 1 0 1 1 2 0 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax 21 23 24 20 23 18 20 20 15 16 18 20 14 14 16
Tax 5 6 6 5 6 5 5 5 4 4 4 5 -1 4 4
Net Profit 16 18 18 15 17 14 16 16 11 12 14 15 15 10 12
EPS 7.77 8.43 8.48 7.12 8.17 6.47 7.49 7.45 5.37 5.79 6.75 7.26 6.97 4.50 5.59

Windlas Biotech Cash Flow Screener - Liquidity Fundamentals

Screen WINDLAS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2025-March, operating activities generated ₹68, and net cash flow was an outflow of ₹5.

Over the same period, investing activities used ₹74 and financing activities provided ₹1.

Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March

Cash from Operations and Investing

Operating Activities 68 109 61 9 12 25 19 35
Investing Activities -74 -92 -14 -155 -20 -14 -7 -11

Financing and Net Cash

Financing Activities 1 -15 -44 130 1 -5 -6 -26
Net Cash Flow -5 2 3 -15 -8 5 6 -2

Windlas Biotech Shareholding Pattern Screener

See Windlas Biotech shareholding pattern with promoter, FII, and DII holdings. Check Windlas Biotech promoter holding and ownership changes for WINDLAS on TickJournal, and see how institutional stock price moves affect the market.

In 2025-Mar, promoters held 62.34%, foreign institutions 1.52%, domestic institutions 10.89% and the public 21.36%, spread across 46,383 shareholders.

The shareholder count was 46,383 in 2025-Mar, compared with 45,887 in 2025-Jun.

Item 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec

Promoter Holding

Promoter Holding 62.34% 62.34% 61.99% 61.99% 62.82% 62.51% 62.51% 62.51%

Institutional Investors

FII Holding 1.52% 1.44% 1.11% 0.93% 1.18% 1.59% 2.00% 1.55%
DII Holding 10.89% 11.21% 11.43% 11.44% 11.82% 10.35% 9.58% 10.26%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 21.36% 20.87% 21.30% 21.29% 21.19% 21.76% 21.80% 21.54%
Other Holding 3.89% 4.14% 4.17% 4.35% 3.00% 3.79% 4.11% 4.14%
Shareholder Count 46,383 45,887 45,433 45,461 51,277 45,824 45,706 46,590

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Windlas Biotech. Windlas Biotech dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹5.80 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹5.80 and ₹5.50 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹5.80 0.80%
2024-March ₹5.50 0.53%
2023-March ₹4.00 0.78%
2022-March ₹3.50 1.56%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Windlas Biotech Stock Index Membership - Nifty & Sensex

See which indices include Windlas Biotech stock. Check WINDLAS index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 2 indices, including BSE INDEX BSE HC.

Among the benchmarks tracked are BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE INDEX BSE HC
BSE INDEX SMLCAP

Windlas Biotech Market Events Screener - Corporate Actions

Get Windlas Biotech corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Windlas Biotech stock events that may affect WINDLAS share price, along with derivatives, futures and options activity and sector gainers.

12 corporate actions are listed, the most recent entry being Dividend dated .

It is followed by Dividend dated and Dividend dated .

Announcement Date Record Date Event Type Information Price Impact
Dividend ₹ 3.50 /share 7.39%
Dividend ₹ 4.00 /share 52.59%
Dividend ₹ 5.50 /share 60.37%
Annual General Meeting NA 5.13%
2026-02-05 2026-02-05 Quarterly Result Announcement NA 11.07%
2025-11-06 2025-11-06 Quarterly Result Announcement NA 0.90%
2025-08-12 2025-08-12 Quarterly Result Announcement NA -1.67%
2025-07-28 2025-07-28 Annual General Meeting NA 9.35%
2025-07-21 2025-07-21 Dividend ₹ 5.80 /share -3.48%
2025-05-22 2025-05-22 Quarterly Result Announcement NA -4.12%
2025-02-11 2025-02-11 Quarterly Result Announcement NA -1.36%
2024-11-12 2024-11-12 Quarterly Result Announcement NA -1.01%

Windlas Biotech Competitors Screener - Peer Stocks Comparison

Screen WINDLAS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 426,386 38.21 54,729 9.71% 10,980 53.49
Divis Laboratories 161,936 64.01 9,712 18.67% 2,191 43.80
Torrent Pharmaceuticals 144,523 62.70 11,539 6.99% 1,911 50.03
Dr Reddys Laboratories 108,410 19.25 33,741 16.73% 5,725 53.38
Lupin 106,092 22.06 22,910 13.74% 3,306 56.84
Cipla 101,488 22.07 28,410 7.12% 5,291 31.85
Zydus Life Science 89,605 17.54 23,511 18.55% 4,615 45.58
Mankind Pharma 82,561 45.82 12,744 20.90% 2,007 37.22
Aurobindo Pharma 75,005 20.80 32,346 9.43% 3,484 60.75
Alkem Laboratories 62,861 25.87 13,458 3.70% 2,216 37.74

Windlas Biotech Company Announcements - News & Reports Screener

Screen WINDLAS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 4, 2026.

The next most recent announcements are dated October 4, 2026 and September 27, 2026.

Date Update Actions
2026-10-04 Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot -
2026-10-04 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2026-09-27 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-02-17 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-02-16 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2026-02-16 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2026-02-13 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-02-13 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-02-11 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-02-10 Sub: Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-02-06 Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Recording Of Conference Call -
2026-02-05 Announcement under Regulation 30 (LODR)-Change in Directorate -
2026-02-05 Announcement under Regulation 30 (LODR)-Cessation -
2026-02-05 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-02-05 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-02-05 Unaudited Financial Results For The Quarter Ended December 31 2025 -
2026-02-05 Board Meeting Outcome for Approval Of Financial Results For The Quarter Ended December 31 2025 -
2026-01-29 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-01-28 Board Meeting Intimation for Notice Of The Board Meeting Scheduled To Be Held On Thursday February 5 2026 -
2026-01-22 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,017.90, within a 52-week range of ₹705.75 to ₹1,154.75. The P/E ratio is 22.70 and the P/B ratio is 2.84, with earnings per unit of ₹29.19. Market capitalisation stands at ₹1,532.95 Cr and the dividend yield is 0.80%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 8 balance sheet periods, 15 income statement periods, 8 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.